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Abstract 
CT scans are an integral component of modern radiotherapy treatments, enabling the accurate localisation of the 
treatment target and organs-at-risk, and providing the tissue density information required for the calculation of dose 
in the treatment planning system. For these reasons, it is important to ensure exposures are optimised to give the 
required clinical image quality with doses that are as low as reasonably achievable. However, there is little 
guidance in the literature on dose levels in radiotherapy CT imaging either within the UK or internationally. 
This IPEM topical report presents the results of the first UK wide survey of dose indices in radiotherapy CT 
planning scans. Patient dose indices were collected for prostate, gynaecological, breast, 3D-lung, 4D-lung, brain 
and head/neck scans. Median values per scanner and examination type were calculated and national dose reference 
levels and ‘achievable levels’ of CT dose index (CTDIvol), dose-length-product (DLP) and scan length are proposed 
based on the third quartile and median values of these distributions, respectively.   
A total of 68 radiotherapy CT scanners were included in this audit. The proposed dose reference levels for CTDIvol 
and DLP are; prostate 16 mGy and 570 mGy.cm, gynaecological 16 mGy and 610 mGy.cm, breast 10 mGy and 
390 mGy.cm, 3D-lung 14 mGy and 550 mGy.cm, 4D-lung 63 mGy and 1750 mGy.cm, brain 50 mGy and 1500 
mGy.cm and head/neck 49 mGy and 2150 mGy.cm. Significant variations in dose indices were noted, with 
head/neck and 4D-lung yielding a factor of eighteen difference between the lowest and highest dose scanners. 
There was also evidence of some clustering in the data by scanner manufacturer, which may be indicative of a lack 
of local optimisation of individual systems to the clinical task. It is anticipated that providing this data to the UK 
and wider radiotherapy community will aid the optimisation of treatment planning CT scan protocols. 
 
Keywords: Diagnostic reference levels (DRLs), radiotherapy CT, UK audit 
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Introduction 
The use of Computed Tomography (CT) is an integral component of the radiotherapy treatment planning process 
(Mutic et al 2003, IAEA 2012). The primary function of the planning CT is to accurately map the positions of the 
treatment target and organs-at-risk and, through use of a treatment planning system (TPS), provide electron or 
physical density information that can then be used in treatment plan development and dose calculations. Another 
important factor that needs to be considered in these types of scan is the requirement for the patient to be imaged in 
the treatment position, which often requires the use of specialised equipment to ensure accurate and reproducible 
localisation throughout the radiotherapy pathway. These clinical requirements mean that scan protocols used for 
radiotherapy planning are unique when compared with similar diagnostic CT applications, and often place 
additional technical limitations on the exposure settings and scanner hardware. For example, it is usually necessary 
to scan all patients with the same x-ray tube voltage to ensure accurate conversion from CT number (Hounsfield 
units) to electron density as differences in attenuation induced through changing the beam energy could result in 
errors in the TPS dose calculations. This fixed tube kilovoltage approach may limit the scope for dose and image 
quality optimisation of planning CT scans (Davis et al 2017). It is also important to ensure the scanner hardware is 
compatible with radiotherapy treatment requirements, which will include the need for a flat couch top and may 
require a large scanner bore to accommodate patients on bulky immobilisation equipment. The increased x-ray tube 
to detector distance on large bore CT scanners may impact dose and/or image quality. It is for these reasons that 
almost 20 years ago, the American Association of Physicists in Medicine (AAPM) recommended scan protocols be 
developed that are specific to the disease site being treated (Fraassa et al 1998). The potential for CT protocol 
optimisation in radiotherapy has increased since these recommendations were published, with most therapy centres 
now owning dedicated CT scanners that incorporate many of the features required for planning scans, alongside a 
number of dose and image quality optimisation features found on diagnostic CT scanners such as automatic 
exposure control (AEC) with or without automatic tube current modulation (ATCM) and iterative reconstruction 
(IR). The process of optimisation should ensure that the quality of the CT image is suitable to allow accurate 
outlining of the treatment target and surrounding organs whilst minimising radiation dose received by the patient 
(Davis et al 2017). This requirement for optimisation is also a legal requirement in the UK under the Ionising 
Radiation (Medical Exposure) Regulations 2017 (IRMER 2017).  
Diagnostic reference levels (DRLs), as a tool to support optimisation, have been a European legislative requirement 
for diagnostic imaging procedures since 2000. Recent updates to the regulations have reinforced the requirement 
for DRLs (EU 2014, IRMER 2017). The principle is that if DRLs for CT examinations are appropriately defined, 
average dose indices delivered on individual CT scanners for groups of standard size patients should not 
consistently exceed these reference levels; if they do, an investigation should be undertaken and remedial action 
implemented where appropriate. For CT, Dose Length Product (DLP) and volume CT dose index (CTDIvol) (Huda 
and Mettler 2011) are the dose metrics of choice. Traditionally DRLs have been set on the basis of national or 
international multi-centre audit (Shrimpton et al 2014, PiDRL 2016), with recent guidance from the International 
Commission on Radiological Protection (ICRP 2017) recommending the third quartile of scanner median dose 
indices for the determination of DRLs (note, previous UK national DRLs (NDRLs) have used the third quartile of 
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scanner mean doses (PHE 2016)). An additional aid to optimisation proposed in ICRP Publication 135 is the 
national median value (also known as the ‘achievable dose’ (Brink et al 2012, Iball et al 2017)); this promotes a 
more proactive approach to optimisation to ensure that dose levels are not simply reduced to just meet the national 
DRL, but to ensure the lowest doses achievable. However, with such quantities it is vital to ensure that image 
quality remains commensurate with the intended clinical purpose.  
Reference levels for radiotherapy planning CT examinations have never been defined in the UK and there are very 
few publications worldwide which provide dose data. A recent study compared CTDIvol, DLP and scan length for 
breast planning CT scans only, and included data from six radiotherapy centres in Ireland (50% of the centres in the 
country) (Connor et al 2016). Despite the common clinical task, significant variations in exposure parameters were 
noted and DRLs of 26 mGy for CTDIvol and 732 mGy.cm for DLP were proposed. The requirement for 
optimisation of CT protocols for radiotherapy planning was highlighted as an important issue, even from this 
relatively small sample of six CT scanners. Since CT examinations used for diagnosis have a different clinical 
purpose and scan length to those acquired for radiotherapy planning, the DRLs published by Public Health England 
(PHE) may not be suitable as an optimisation tool in radiotherapy CT (Shrimpton et al 2014, Holroyd and Edyvean 
2018). This is also true of European and international guidance on DRLs for CT imaging, emphasising the need for 
robust large scale national dose audits of radiotherapy CT imaging practice. 
This paper presents the results of the first large scale UK audit of CT doses delivered during planning CT scans, 
with a view to proposing the first UK national reference levels for a range of common clinical sites. The audit has 
been undertaken by a working party formed by the radiotherapy and diagnostic radiology special interest groups of 
the Institute of Physics and Engineering in Medicine (IPEM). The working party remit is to investigate current 
practice, techniques used and doses delivered during imaging for radiotherapy. This publication contains the results 
of the first phase of this audit. 
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Method 
Examination selection and pre-audit questionnaire 
Seven radiotherapy CT scan protocols were initially selected for the dose audit. Common examinations were 
chosen to increase the likelihood of collecting a high volume of dose index data. These were: head and neck, brain, 
breast (no nodes), prostate (no nodes), gynaecological (no nodes), lung 3D and lung 4D. Examinations that covered 
the nodes were excluded from the audit as it was anticipated that variations in scan length could be significant 
between patients; by requesting ‘no node’ examinations, it was felt that practice would be more standardised (and 
nodal examinations would simply be an extension of these protocols). Associated guidance that was provided for 
these examinations is given in Table 1. 
Table 1: CT protocols and guidance issued with the data collection form. 
CT protocol Guidance 
Breast No nodes 
Gynaecological No PA nodes 
Head and neck Nasal/oral cancers which include neck nodes 
Lung 3D  
Lung 4D  
Brain Excluding stereotactic planning scans; excluding palliative 
Prostate No nodes 
A pre-audit questionnaire was issued to 73 UK radiotherapy centres, consisting of 63 National Health Service 
(NHS) centres and 10 private providers. Some of these centres had multiple sites. The purpose of the questionnaire 
was to collect information on CT scanner types in use in radiotherapy centres, to confirm whether the selected 
examinations represented the most common CT examinations, to confirm if patient weight information was 
available, to identify the extent of paediatric imaging/treatment, and to establish whether centres would participate 
in a national dose audit. 
Data collection 
A Microsoft Excel
TM
 (Washington, USA) data collection form was developed based on previous national dose 
audits for SPECT CT and PET CT (Iball et al 2017), and C-spine CT (Holroyd and Edyvean 2018). For each 
examination type the form required information on the CT scanner make, model and age. Scan protocol details 
requested included tube voltage, tube current, whether AEC was used, whether helical or axial scanning was 
employed, acquisition field of view, pitch and collimation settings. Parameters relevant to image formation were 
collected including image slice thickness, reconstruction algorithm, reconstruction field of view, and whether 
iterative reconstruction was used. Information about other imaging modalities, use of intravenous contrast agent 
and the accuracy of scanner displayed CTDIvol compared with measured values was also collected. Centres were 
asked to provide CTDIvol, DLP and scan length values for individual patients, ensuring that the data set for each 
examination included a minimum of 10, and up to 30 adult patients. Patient weight was requested where available. 
Dose from CT localiser radiographs was to be excluded where possible.  
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Four different instruction sheets were produced showing where to find the relevant data on the different makes of 
scanner. The aim of this was to make data collection easier for participating centres and to ensure the required data 
were collected in a consistent manner. The call for data, together with accompanying forms and instructions, was 
distributed to radiotherapy centres by e-mail using a contact list for heads of Radiotherapy Physics or Medical 
Physics departments held by the IPEM, the mail-bases for UK Medical Physics and Engineering and the UK CT 
Users Group, and via a contact list for radiotherapy managers held by The Society and College of Radiographers. 
Completed data collection forms were received over a period of 3 months from March to May 2017. After that time 
centres who had submitted data sets with dose indices from fewer than 10 patients were contacted, and allowed 
another month to provide more data.  
Data review and processing 
During the processing phase, data sets from each centre were anonymised and allocated unique identifiers. Any sets 
with dose indices for fewer than 8 patients were excluded. The reason for this was that patient weight or size has a 
significant impact on dose where AEC is used and small numbers of patients cannot be representative of the typical 
dose delivered by a single scanner (Shrimpton et al 2014). Where centres had submitted several scan protocols for 
a given examination which were clearly for different clinical purposes, these sets were retained as separate data 
(and given alphabetical subscripts in their unique identifiers to distinguish them). If centres submitted separate data 
for the same clinical indication, but there was only a minor difference in scan protocol (e.g. with or without 
contrast, but all other parameters were the same), the data sets were combined into a single pool.  
All data were reviewed to check for anomalies, and centres contacted to confirm accuracy where necessary. All 
processed data were then copied into a custom built Microsoft Access
TM
 (Washington, USA) database. The 
database was interrogated with a Matlab
TM
 (MathWorks, Massachusetts, USA) graphical user interface during 
analysis. Median and mean values of CTDIvol, DLP and scan length were calculated for each examination data set 
per scanner. Where patient weight was provided, the impact from very large and small patients on median and 
mean values was evaluated. It was noted that when calculating mean dose indices for a particular scanner a large 
dose from a heavy patient could have a disproportionate effect on the result. Therefore the decision was made to 
use median values from each scanner data set when processing the data, which is in line with new guidance from 
the ICRP (ICRP 2017). 95% confidence intervals were calculated and are shown as error bars on all plots with 
median values. Scanner mean values are also included to allow for cross referencing against other published values 
where scanner means have been used (e.g. Connor et al 2016). 
From technical information supplied by Toshiba Medical Systems Ltd it was known that scanners running software 
version 4.63 or earlier, indicated CTDIvol is the maximum value delivered during a scan, not the mean as is the case 
on all other systems (Tsalafoutas et al 2012). Conversely, mean CTDIvol values are used to calculate DLP. Centres 
with Toshiba scanners were asked to provide the software version so that those reporting maximum CTDIvol values 
could be identified and excluded from the calculation of national reference values if tube current modulation was 
used, since these systems could significantly skew the proposed values. DLP from these scanners were retained as 
they are calculated in the same way as all other scanner models surveyed. 
Page 6 of 29AUTHOR SUBMITTED MANUSCRIPT - PMB-107287.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For brain scans and head and neck scans, some systems were configured to indicate CTDIvol values for a 16 cm 
diameter phantom, whilst others gave it for a 32 cm diameter phantom. For ease of comparison and presentation of 
results, the data for CTDIvol 32cm and DLP 32cm were multiplied by a size-specific dose estimate factor of 2.06 
(AAPM, 2011) so that they could be compared with the CTDIvol 16cm values. For brain scans, this matches the 
methodology used in another recent UK CT dose audit (Iball et al 2017) and also allows comparison against dose 
indices for diagnostic quality head CT scans. The same correction factor was applied for head and neck scans for 
consistency. 
National values of median, first and third quartile, minimum and maximum were calculated using the whole data 
set for each examination type. The third quartile values were rounded to produce recommended national reference 
levels and median values were rounded to provide ‘achievable levels’. To propose national reference levels and 
‘achievable levels’ for any clinical indication, a minimum of 10 data sets (with at least 8 patient’s worth of 
exposure information) from 10 different systems were required. 
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Results 
Pre-audit questionnaire 
A total of 59 centres responded, corresponding to 80% of the identified UK radiotherapy centres. The responders 
covered 92 radiotherapy CT scanners of which the percentage share of scanner manufacturers was 24% from 
Siemens Healthineers, 23% from GE Healthcare, 30% from Philips Healthcare and 23% from Toshiba Medical 
Systems Ltd. For each of the suggested examinations, the number of centres confirming that they carried out those 
scan types was: 54 for head and neck; 44 for brain; 57 for breast (no nodes); 56 for prostate (no nodes); 46 for 
gynaecological; 53 for lung 3D and 48 for lung 4D. Additionally 9 centres identified abdominal scans as being 
relatively frequent. Fewer than half the centres said that they routinely recorded patient weight and many do this 
only for certain sites, for example head and neck so as to monitor patient weight loss during the course of 
treatment. Only 16 centres (27%) indicated that they imaged paediatric patients.  
After review of the responses the decision was made to include only doses from adults in the main audit but to 
consider a subsequent, but targeted audit for paediatric patients. Since many centres did not have patient weight 
available then the collection of patient weight information would be desirable but not mandatory; the abdomen 
examination was not included in the selected list as the number of centres that identified this as a frequently used 
protocol was low; and the initial choice of the seven selected examinations was ratified. 
Audit of UK radiotherapy treatment planning CT scans and proposed reference levels 
A total of 55 centres submitted data, but one was excluded as sample sizes were insufficient for inclusion in the 
analysis. From the 54 centres remaining, data was submitted for 68 different CT scanners (see Table 2). The age of 
the scanners ranged from 1 to 12 years with the mean age being 6.8 years. Typically, each scanner data set 
contained sufficient data for 6 or 7 types of examination (or variations thereof). The lowest number of full data sets 
per scanner was one (i.e. suggesting a scanner that may only be used for one type of scan, such as breast), and the 
highest number was 10 (note, this centre submitted multiple data sets for variations on the given clinical indications 
e.g. with and without contrast, breath-hold and free-breathing). Centres were also asked to provide information on 
CTDIvol accuracy, with 34 scanners (50%) giving data that demonstrated a CTDIvol accuracy range from 0 to 19%, 
with the mean being 7% (note, it was not clear if data was a positive or negative deviation from the displayed 
value, so only the absolute deviations were considered). These are within typical manufacturer tolerances for this 
metric, and demonstrate that no system was operating outside normal limits. As data was not available for all 
systems, no corrections have been applied to the data in this study. A summary of the data collected is presented in 
Table 3, and details of typical CT scan parameters are given in Table 4; further information related to individual 
clinical indications are also given over the following sections. It should be noted that not all centres provided 
CTDIvol, DLP and scan length data (or in the case of older Toshiba scanners, CTDIvol values were excluded if they 
represented the maximum value for a protocol that used tube current modulation), so the sample sizes for each 
metric in Table 3 are not identical. Table 5 gives the ratios of the maximum-to-minimum and third-to-first quartile 
scanner median CTDIvol, DLP and scan length values for each examination. This demonstrates the wide variation in 
practice for nominally the same clinical task. Table 6 presents the proposed UK reference and achievable levels for 
the seven different adult radiotherapy treatment planning CT scans that were considered in this study.   
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Table 2: Number of scanners by manufacturer and model including the number using iterative reconstruction (IR). 
Scanner manufacturer and model Number (%) Number with IR 
GE Healthcare 
 Lightspeed RT 16 10 (15) 0 
 Discovery CT 590 5 (7) 3 
Philips Medical 
 Brilliance Big Bore 27 (40) 5 
Toshiba Medical Systems Ltd 
 Aquilion LB 14 (20) 1 
Siemens Healthineers 
 Definition AS 4 (6) 1 
 Open 7 (10) 1 
 Edge 1 (2) 0 
Total 68 (100) 11 
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Table 3: Volume corrected Computed Tomography Dose Index (CTDIvol), Dose-Length Product (DLP) and scan length for the examinations audited using scanner 
median values. PD is the Phantom Diameter used for the CTDIvol value, Npatients is the total number of patients that data was submitted for, and Nscanners is the number 
of scanners in the sample for the given metric. Median, minimum and maximum values are based on the distribution of scanner median values. 
Examination 
PD 
(cm) 
Npatients 
CTDIvol (mGy)
1
 
 
 
DLP (mGy.cm)  Scan length (mm) 
Nscanners Median Min. Max.  Nscanners Median Min. Max.  Nscanners Median Min. Max. 
Breast  32 1527 52 7.5 2.3 20.6  62 283 92 763  59 332 248 407 
Gynaecological 32 711 27 12.1 6.0 32.4  36 510 207 1431  33 377 303 474 
Lung 3D 32 953 42 9.6 3.9 24.2  51 410 149 996  49 367 308 454 
Lung 4D 32 664 39 35.6 11.6 194  41 1174 346 6426  36 326 174 640 
Prostate 32 1278 54 12.9 7.0 33.8  64 419 280 1319  62 305 160 523 
Brain 
16 755 36 39.8 19.1 91.3  41 1043 179 2888  38 250 186 420 
32 199 9 26.7 14.4 45.8  11 785 102 1336  11 248 214 422 
All brain data
2
  16 954 45 41.6 19.1 94.4  52 1107 179 2888  52 248 186 422 
Head and Neck 
16 265 12 21.5 7.8 84.8  13 990 302 3291  13 383 312 534 
32 807 34 13.2 4.6 69.5  39 525 166 2470  39 400 290 585 
All H&N data
2
  16 1072 46 25.5 7.8 143  52 1077 302 5088  52 398 290 585 
  
                                                          
1
 Note, CTDIvol maximum values from Toshiba CT scanners running software version 4.63 or earlier were excluded. 
2
 CTDIvol and DLP values for 32 cm phantom converted to 16 cm phantom values using conversion factor 2.06. 
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Table 4: A summary of the key scan parameters used for the different CT examinations, including tube kilovoltage (kV), use of automatic exposure control (AEC) 
or fixed tube current (mA), iterative reconstruction (IR), and whether axial or helical scans were performed. Most frequent values (mode) for pitch (where 
appropriate) and radiation beam width are given, along with the range of image slice widths and scan/reconstruction fields of view (FOV). 
Examination Nscanners 
kV 
(mode) 
mA control 
IR 
Scan mode Radiation 
beam width 
(mode, mm) 
Image slice 
width  
(range, mm) 
Scan FOV 
(range, mm) 
Recon. FOV 
(range, mm) 
AEC Fixed  Axial Helical 
Helical pitch  
(range, mode) 
Breast  62 120 58 4 11 1 61 0.688-1.375, 0.938 24 1.25-5.0 350-820 350-700 
Gynaecological 36 120 36 0 5 0 36 0.690-1.375, 0.938 24 2.0-5.0 400-820 400-700 
Lung 3D 51 120 48 3 9 1 50 0.562-1.375, 0.938 24 2.0-5.0 350-820 350-700 
Lung 4D 41 120 8 33 3 8 33 Variable 24 1.25-3.0 436-820 360-606 
Prostate 64 120 
(a)
 63 1 9 0 64 0.688-1.375, 0.813 24 1.25-3.0 400-820 400-700 
Brain 52 120 
(b)
 21 31 8 3 49 0.438-1.375, 0.938 12 1.25-3.0 250-820 250-611 
Head and Neck 52 120 
(c)
 41 11 9 1 51 0.438-1.375, 0.938 24 1.25-3.0 350-820 350-700 
Table footnotes  
(a) Three prostate scan protocols, intended for fiducial markers, used 140 kV. 
(b) Two brain scan protocols used 140 kV. 
(c) One head and neck scan protocol used 140 kV. 
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Table 5: Maximum-to-minimum and third-to-first quartile ratios for median values from each scanner in this study. 
 Maximum-to-minimum ratio 
 
Third-to-first quartile ratio 
Examination CTDIvol DLP Scan length 
 
CTDIvol DLP Scan length 
Breast  9.0 8.3 1.6 
 
1.9 1.9 1.1 
Gynaecological 5.4 6.9 1.6 
 
1.6 1.6 1.1 
Lung 3D 6.2 6.7 1.5 
 
2.0 1.9 1.1 
Lung 4D 16.7 18.6 3.7 
 
2.8 2.2 1.1 
Prostate 4.8 4.7 3.3 
 
1.6 1.6 1.3 
Brain 4.9 16.2 2.3 
 
1.5 1.6 1.3 
Head and Neck 18.3 16.9 2.0 
 
2.6 2.8 1.1 
 
Table 6: Proposed reference and achievable levels in terms of CTDIvol, DLP and scan length for radiotherapy 
treatment planning CT scans performed in the UK. 
Examination 
PD 
(cm) 
Proposed reference level  Achievable level 
CTDIvol 
(mGy) 
DLP 
(mGy.cm) 
Scan 
length 
(mm) 
 
CTDIvol 
(mGy) 
DLP 
(mGy.cm) 
Scan 
length 
(mm) 
Breast 32 10 390 360  8 280 330 
Gynaecological 32 16 610 400  12 510 380 
Lung 3D 32 14 550 390  10 410 370 
Lung 4D 32 63 1750 340  36 1170 330 
Prostate 32 16 570 340  13 420 310 
Brain  16 50 1500 290  42 1110 250 
Head and Neck  16 49 2150 420  26 1080 400 
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Breast scans 
A total of 62 scanners provided data on breast treatment planning scans. In the majority of centres, helical scans 
(61) were acquired with AEC (58). The use of iterative reconstruction was most common in the breast scanning 
data (11 scanners using it), and the most common image slice thickness was 3.0 mm (25 scanners). Figure 1 
demonstrates the impact of iterative reconstruction, as currently implemented on the scanners in this study, with the 
systems using these techniques distributed amongst those using filtered back projection i.e. there is no clear 
evidence that iterative reconstruction is being implemented to reduce patient doses at this stage. However, the 
limited data available in this study makes it difficult to draw any statistically significant conclusions, and it may be 
worth further study in follow up surveys when it is expected that more scanners will have this feature implemented. 
Only 2 centres indicated that they sometimes use IV contrast.  
 
Figure 1: Breast scanning CTDIvol comparison with filtered back projection or iterative reconstruction indicated for 
each scanner. Systems are ordered by increasing DLP, and Toshiba CT systems reporting maximum CTDIvol and 
using ATCM are indicated (*). Each bar represents the median scanner value, and error bars are defined by the 
95% confidence intervals. 
For comparison with the study by Connor et al (2016), scanner mean values were also used to calculate equivalent 
reference values for breast CT planning scans (as given in Tables 3 and 6). The achievable (median) CTDIvol was 
8.4 mGy (range 2.4 to 19.9 mGy), with a reference value (third quartile) of 12.5 mGy. For DLP the achievable dose 
was 341 mGy.cm (range 101 to 740 mGy.cm), with a reference value of 432 mGy.cm, and for scan length the 
achievable value was 334 mm (range 258 to 411 mm) with a reference value of 371 mm. Comparing these with the 
values given in Tables 3 and 6, it is clear that ‘average’ dose indices are 10-20% higher when scanner mean is used 
due to the impact of patient size (with median being more resilient to ‘high’ doses on large patients in the sample), 
whilst scan length values are comparable between data sets as these are not exponentially dependent on patient size.  
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Five centres provided separate data for standard ‘free-breathing’ breast scans and deep-inspiration breath hold 
(DIBH) scans. From this very limited data, 2 centres scanned DIBH patients with the same protocol as for free-
breathing, whilst three centres used lower dose DIBH protocols (but same scan range). For this reason, the separate 
DIBH data sets were not included in this analysis; however, it may be worth inclusion as a separate clinical 
indication in future dose surveys, to establish if there are any real differences in scan protocols being used, 
especially as the technique becomes more common. In some centres DIBH were included in the free-breathing set 
and were indicated in the comments field; these data were included in the analysis as the scans were acquired with 
the same protocol over the same scan range (but with the patient coached to hold their breath during acquisition). 
Gynaecological 
Sufficient data was submitted from 36 scanners, with one centre submitting two sets of data from two different 
protocols distinguishing between cervical and endometrial scans. All scanners used helical scanning mode and 
AEC, but only five used iterative reconstruction. One scanner used an image slice thickness of 5 mm, with the rest 
equally divided between image slice thicknesses of 2.0, 2.5 and 3.0 mm. IV contrast was ‘always’ used on 10 
scanners, and ‘sometimes’ on a further 19 systems.  
Four scanners that used two scan phases are spread throughout the dataset (i.e. not clustered around particular dose 
values nor are they obvious outliers), and the dose indices are similar to those from other scanners from the same 
vendors that use similar protocols apart from the number of phases. For two of these four scanners the first phase is 
a rectal check, before proceeding to the full scan. One of these centres stated the DLP for the rectal check, which 
typically contributed around 7% of the total DLP for the 15 (of 20) patients for which this was performed. Another 
of these four centres stated that an additional contrast scan is sometimes performed, however the number for which 
this was performed in the submitted dataset is not known. 
Lung scans (3D & 4D) 
Data from 51 scanners were submitted for 3D lung treatment planning. The majority use helical scanning mode 
(50) and AEC (48). The most common image slice thicknesses were 3.0 mm (20 scanners) and 2.0 mm (19 
scanners). Nine scanners used iterative reconstruction. Fourteen scanners use IV contrast routinely on 3D lung 
patients, with a further 24 stating it was used sometimes. 
Forty-one scanners submitted data for 4D lung scans. The technique used for acquiring these scans was highly 
dependent on the manufacturer of the CT system. This has a strong influence on the dose indices for the scan, as 
demonstrated in Figure 2. It is clear that the protocols and scan technique implemented on the Philips Big Bore tend 
to yield the lowest CTDIvol and DLP values, whilst the protocols implemented on Toshiba and GE systems tend to 
be the highest. Eight of these scanners use axial techniques to acquire the images (all GE), whilst the remaining 33 
scanners from the other three vendors acquire slow helical scans. Most protocols used variable parameters that are 
determined by the breathing rate of individual patients (such as variable pitch on the Philips Big Bore systems). 
Most 4D scans used fixed mAs techniques (33), with only three scanners using iterative reconstruction. The most 
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common image slice thickness was 3.0 mm (23 scanners). Eighteen scanners use IV contrast routinely, with a 
further six stating it was used sometimes.  
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(a) 
 
(b) 
 
(c) 
Figure 2: 4D lung scanning (a) CTDIvol, (b) DLP and (c) scan length comparisons for the systems included in this 
study, with vendor indicated for each scanner. Systems are ordered by increasing DLP, and Toshiba CT systems 
reporting maximum CTDIvol and using ATCM are indicated (*). Each bar represents the median scanner value, and 
error bars are defined by the 95% confidence intervals. 
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In the combined (3D and 4D) lung data sets, seven scanners submitted data for two phase protocols whereby both a 
4D and 3D scan were performed as part of the overall treatment planning examination. Figure 3(a-b) shows a 
comparison of dose indices between the ‘standard 3D’ scan and those performed as part of the 4D protocol (‘3D for 
4D’), whilst Figure 3(c) shows a comparison of scan lengths for the standard 3D, 4D and ‘3D for 4D’ scans. Based 
on this limited data set, it appears that the same protocol is used to acquire the 3D scans in these two examinations 
(with the exception of one centre that appears to use a lower dose when the 3D scan is part of a 4D study). Out of 
these seven scanners, it is also apparent that three of these centres use a shorter scan length for the 4D acquisition 
(and hence, potentially a lower dose), indicating that the 4D imaging tends to focus over the specific regions of 
interest (e.g. tumour), whilst the 3D scan most likely provides the extended anatomical coverage required for the 
treatment planning system. 
Prostate (no nodes) scans 
There were 64 data sets submitted for prostate scans. Three centres submitted data from two different protocols, 
with the alternative protocol being for scanning patients with fiducial markers (all set to scan at 140 kV). Nineteen 
centres (30%) stated that a short scan to check the degree of bladder and/or rectum filling was performed prior to 
the full planning CT; any dose index information provided separately for this check scan was excluded from the 
results shown in Table 3 (note, this was usually a low dose scan). Just one centre checked the filling of the bladder 
using ultrasound. The majority of centres did not use IV contrast for prostate scans, though 10 centres indicated that 
it was used ‘sometimes’. In 10 centres MRI was used ‘when required’, with two centres commenting that MRI was 
used for patients with hip prostheses. All except one scanner used AEC to set tube current. 
Brain scans 
A total of 52 data sets were submitted for brain scans, with 41 scanners giving CTDIvol and DLP values for a 16 cm 
diameter phantom and the remaining 11 scanners indicating a 32 cm phantom. Fifteen centres routinely use 
intravenous contrast agent and MRI was used to provide supplementary imaging in 22 centres. One centre 
submitted two data sets for separate helical and axial scan protocols, but did not provide information as to how the 
appropriate protocol is selected.  
Head and neck scans 
A total of 52 data sets were submitted for head and neck scans, with 13 scanners giving CTDIvol and DLP values 
for a 16 cm diameter phantom and the remaining 39 scanners indicating a 32 cm phantom. Intravenous contrast 
agent was used at most centres (43). Three centres submitted separate data sets for contrast and non-contrast scans. 
For the purposes of data analysis, the contrast and non-contrast data sets were merged for each scanner as all other 
protocol settings were the same.  
Some centres used other forms of imaging to support treatment planning for head and neck patients, though this 
was not routine on all patients; 17 centres (33%) indicated MRI images were acquired for some patients, and seven 
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centres (14%) sometimes acquire PET scans. One centre stated that they were using a second reconstruction at 
smaller field-of-view to assist with outlining. 
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(a) 
 
(b) 
 
(c) 
Figure 3: (a) CTDIvol and (b) DLP comparisons between 3D scans acquired for lung treatment planning, and those 
acquired as part of a 4D lung CT examination (note, 4D dose indices are not displayed for clarity as they are 
approximately three times higher). (c) Scan length comparisons between 3D, 4D and ‘3D for 4D’ scans. Each bar 
represents the median scanner value, and error bars are defined by the 95% confidence intervals. 
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Automatic exposure control, tube current modulation and patient size  
The use of AEC and tube current modulation is wide spread but not universal across centres and scan protocols. 
Whilst all centres used AEC for gynaecological scans, several still use fixed tube current for other clinical 
indications (see Table 4). For head and neck scans, where potentially AEC would help maintain more consistent 
image quality through the significant variations in patient cross-section, 11 of the 51 centres used fixed tube 
current. Figure 4 shows how median CTDIvol for these scanners is evenly distributed amongst the systems that used 
AEC. This potentially highlights issues with the optimisation of scan protocols as not only will image quality be 
highly variable throughout the scan volume (depending on the individual patient cross-section), but there are also 
significant variations in dose indices due to the configuration of CT protocols; for example, scanners 2 and 38 are 
the same model of Toshiba scanner (installed within a year of each other at different centres), but gave the lowest 
and highest CTDIvol in the fixed tube current group, due to a factor of three difference in tube current settings (note, 
neither used iterative reconstruction).  
 
Figure 4: Head and neck CTDIvol values (16 cm phantom) demonstrating the use of AEC or fixed tube current. 
Systems are ordered by increasing DLP, and Toshiba systems reporting maximum CTDIvol and using ATCM are 
indicated (*). Each bar represents the median scanner value, and error bars are defined by the 95% confidence 
intervals. 
Another example of the effect of AEC and tube current modulation is shown Figure 5 for 3D lung scans. All but 
three of the systems use AEC to determine exposure factors (centres 7, 26 and 55 use fixed exposure factors). In 
this data set, there appears to be some clustering of dose indices from the different manufacturers with the Philips 
systems towards the lower end of the scale, the GE systems at the upper end, and the Toshiba and Siemens systems 
spread amongst the middle of the data set. This trend was consistent across most clinical indications in this study. 
This clustering likely reflects the configuration of default scan protocols, rather than any fundamental differences in 
technology; with appropriate optimisation, it is expected that such effects would be removed from the data without 
any detriment to image quality (as evidenced by some scanners breaking this trend e.g. scanner numbers 63 
(Toshiba), 23 (Siemens) and 31 (GE) are noticeably lower dose than other similar systems from the same vendor). 
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 Figure 5: 3D lung scanning CTDIvol comparisons for the systems included in this study, with vendor indicated for 
each scanner. Systems are ordered by increasing DLP, and Toshiba systems reporting maximum CTDIvol and using 
ATCM are indicated (*). Each bar represents the median scanner value, and error bars are defined by the 95% 
confidence intervals. 
Figure 5 also demonstrates the potential impact when trying to use CTDIvol in dose audits for older Toshiba 
systems. With the data ordered by increasing DLP (which is always based on the mean CTDIvol), the Toshiba 
scanners that report maximum CTDIvol become apparent as significant peaks within the data (compared with 
neighbouring, similar DLP scanners). When comparing scanner median dose indices with the CTDIvol reference 
values proposed in this study, it is therefore important to account for such effects; in practice on older Toshiba 
scanners, it will probably be appropriate to compare with the reference DLP and scan length values only.  
Combined with the configuration of the AEC system, typical patient size for the given clinical indication will 
determine the dose index on each scanner. For prostate CT scans (where both dose index and weight were provided 
for 25 systems), median CTDIvol per scanner and individual patient dose indices were compared when plotted 
against weight (see Figure 6). Patient weight range was large (38 to 179 kg) for the sample of 431 patients, and 
CTDIvol values clearly increased with patient size, as would be expected with AEC. When median CTDIvol and 
median weight are considered, the average scanner data is more tightly clustered around 80-85 kg, but demonstrates 
a wide variation in dose due to the configuration of the CT scanner. To illustrate the potential impact of weight on 
the determination of reference values (note, all data irrespective of whether weight was provided or not was used to 
determine the reference values given in Table 6), Table 7 shows the results for the subset of data where weight 
information was provided, compared with the whole data set both in terms of scanner median values (as per ICRP 
recommendations) and scanner means. From the limited ‘with weight’ data set, it is clear that the ‘typical’ patient 
(83 kg) for this examination is larger than the historical ‘standard’ size patient (70 kg), which is likely reflective of 
both the changing UK population and the specific clinical indication. This combined with the limited number of 
patients that can be audited for these types of examination render it impractical to set strict limits on patient weight 
for inclusion in this audit. Table 7 also  demonstrates that patient size has a strong influence on dose index 
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reference values when scanner mean values are used, with the DLP reference level 11% higher than the value 
obtained with scanner medians in the ‘with weight’ data set; this is consistent with the results for the breast data. 
This also demonstrates that using scanner median is a robust technique for dose audit in the absence of patient size 
information as the two data sets yield reference values within 4% of each other, whilst using scanner means results 
in discrepancies of up to 13%. This will be due to scanner median being more resistant to outlier patients who are 
either very large or very small. 
 
Figure 6: Individual CTDIvol versus patient weight for the sub-set of prostate examination data where weight was 
provided compared with scanner median CTDIvol plotted as a function of scanner median weight. A linear fit to the 
individual patient data is shown to guide the eye. 
Table 7: A comparison of prostate reference levels determined with and without patients’ weight information using 
scanner median and mean values. 
Data set Nscanners 
CTDIvol (mGy) 
 
Weight (kg) 
‘Scanner median’ data  ‘Scanner mean’ data  
Median 
Third 
quartile 
 Median 
Third 
quartile 
 Median 
Third 
quartile 
‘With weight’ only 25 13.1 16.9  13.8 18.8  83 86 
All data 54 12.9 16.2  13.5 16.7  - - 
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Discussion 
The wide range of CTDIvol, DLP and scan length values shows that there is clearly scope to optimise radiotherapy 
CT scan protocols in the UK.  Head and neck and 4D lung scans show the greatest variation between centres with 
the highest dose scanner delivering approximately 18 times that seen on the lowest (CTDIvol or DLP). For 
examinations showing the least variation in dose indices between scanners, namely prostate, gynaecological and 3D 
lung, the maximum to minimum factor is closer to five. For these scan types AEC usage is more prevalent and 
appears to be effective at reducing dose index variability. It is also apparent that the central 50% of data appears to 
be less variable with ratios between the 3
rd
 and 1
st
 quartile taking values of between 1.5 and 2.0 for all exams with 
the exception of head and neck and 4D lung, which can be up to a factor of 2.8. The reduced variability in the 
central 50% of scanners may be indicative of centres that are potential outliers; this could either be due to the 
scanners being configured to use either particularly ‘high dose’ settings, or very low dose settings where the 
acceptability of image quality may become more of a concern. 
Based on the results of this audit, there is some evidence of scanners supplied by a given vendor operating on 
similar scan protocols, suggesting default protocols are in use without local adjustment and optimisation. This is 
demonstrated through the clustering of dose index values in Figures 2 and 5, but was also observed in other 
examination types. Dose indices for 4D lung scans were seen to have particularly strong manufacturer dependence 
which will be related to the different scan techniques used by each vendor to generate these image sets. However, 
there are several cases where centres have clearly optimised scan protocols locally as they do not lie within the 
usual cluster for that vendor; this indicates that the scope for optimisation is not purely defined by the make and 
model of scanner installed in the department, and relatively simple changes to scan protocols may enable real 
patient benefits (be it through reduced patient dose or more optimal image quality). It has also been noted that 
although 16% of scanners have iterative reconstruction available, the range of dose indices delivered by scanners 
using this technology currently matches that where filtered back-projection is used. Hence, there is currently no 
evidence of notable dose reduction resulting from the use of iterative reconstruction in radiotherapy planning CT 
scans.  
The wide spread of dose indices across the sampled data, the clustering by vendor and the variability in 
implementation of new technology clearly justifies the need for national reference levels to be set as a tool to aid 
scan protocol optimisation. Dose index (CTDIvol and DLP) and scan length reference levels based on the third 
quartile of the distributions of scanner median values have been proposed (like DRLs in diagnostic practice), 
alongside achievable levels (based on the median of the scanner median distributions). It is hoped that by making 
use of both of these values, it will be possible to improve CT practice in radiotherapy departments across the UK 
by not only promoting ‘compliance’ with the reference levels, but by also utilising the achievable values as a 
further benchmark. For example, it may be anticipated that the oldest CT equipment should be able to comply with 
the reference levels but may struggle to match the achievable level, whilst the newest technology should be able to 
yield dose indices at, or below, the achievable standard. Nevertheless, as is the case with all optimisation work, it is 
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important to ensure that compliance with these reference levels does not come at the expense of acceptable image 
quality for the clinical task at hand. However, given the range of data and the similarity of the many systems in this 
study, it is unlikely that image quality and reference level compliance would represent a problem for the equipment 
in UK radiotherapy centres. It is hoped that by making this data available, future surveys of radiotherapy CT 
planning scans will reveal much less variation in practice across the UK, and better optimisation of the technology 
available on modern CT scanners. Future surveys may also expand the range of protocols to include new 
techniques such as deep-inspiration breath-hold, and there may be a need to develop reference levels for 
Stereotactic Ablative Radiotherapy (SABR) planning scans, where thinner slices may be required for planning 
purposes (which in turn will impact on image quality). 
Another factor that contributes to the level of dose observed on each scanner is the variability in patient size, which 
in turn may depend on the clinical indication. Traditionally, national dose audits have specified that only patients 
falling within a particular ‘standard’ weight range (typically 50 to 90 kg) be included, though more recent reviews 
have taken the pragmatic view that this is no longer required provided sample size is greater than 10 patients per 
system (Hart et al 2012, Shrimpton et al 2014). Inclusion of patients based on ‘standard weight’ can prove 
problematic where, as evidenced by the pre-audit questionnaire, many centres do not routinely record this 
information or have it readily available at the time of data collection. Other alternatives such as patient cross-
sectional area may be useful indicators of patient size for routine dose audit, but are difficult to implement in 
practice due to the time required to make such measurements and the difficulty in defining exactly where in the 
patient scan volume this should be evaluated. It is also true in the case of radiotherapy planning scans that the 
clinical condition may have a significant impact on ‘typical’ patient size, yielding patient groups that do not fit 
within the ‘standard’ patient range that has been used historically for diagnostic imaging patient dose audits. 
As patient weight information was not available for all systems in this audit, the impact of patient size was 
investigated on a more limited set of data. Where AEC was used, CTDIvol clearly increases with increasing patient 
weight, and it has been demonstrated that data points at the very low or very high end of the weight and dose index 
range can skew the mean values for any given scanner. Median values are less affected by this, and have been 
shown to be a more robust metric for the purposes of dose audit for these types of examination; for this reason the 
median values per scanner were used to define the proposed reference levels in this study. Whilst this differs from 
some previous national UK dose audits carried out for diagnostic imaging procedures (Shrimpton et al 2014), it is 
in line with recently published international guidance (ICRP, 2017) and is effective in the absence of weight 
information. It has also been a consideration in the latest national audit for C-Spine CT dose indices, where similar 
trends to those reported in this study have been observed (Holroyd and Edyvean 2018). It is important for centres 
that wish to compare their local dose indices against the recommended reference values that the sample size for 
local dose data is sufficiently large, and it is recommended that median values are used for any comparisons. 
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For the reference levels proposed in this work and given in Table 6, there are very few radiotherapy CT reference 
levels published elsewhere that can be used for comparison (either from the UK or internationally). For breast, the 
2016 audit of six Irish radiotherapy centres proposed national DRLS of 26 mGy and 732 mGy.cm for CTDIvol and 
DLP, respectively, using the third quartile of scanner means. Irrespective of whether scanner mean or median 
values are compared with this data, the UK reference values proposed in this study are approximately 40-60% 
lower.  
Table 8 gives a comparison of the proposed radiotherapy planning CT reference levels with the closest equivalent 
diagnostic CT examination UK national DRL. For prostate scans, the proposed reference level of 16 mGy for 
CTDIvol compares well with the diagnostic CT NDRLs of 14 mGy for abdomen and 15 mGy for abdomen and 
pelvis. It should be noted, however, that the UK NDRL values for diagnostic CT scans will be for a different 
clinical task. As might be expected, gynaecological scans have similar proposed reference levels to those for 
prostate, with slightly longer scan lengths as may be expected due to the relative size of the structures that are of 
clinical interest.  
Table 8: A comparison of radiotherapy planning CT scan reference levels with the closest equivalent diagnostic 
CT examination UK national DRL (Shrimpton et al 2014). DLP comparisons should be treated with caution as scan 
lengths may be quite different between these clinical applications. 
Proposed radiotherapy planning scan reference level  Closest ‘equivalent’ diagnostic CT UK NDRL 
Examination CTDIvol (mGy) DLP (mGy.cm)  Examination CTDIvol (mGy) DLP (mGy.cm) 
Breast 10 390  
Chest  
(lung cancer) 
12 610 
Gynaecological 16 610  
Abdomen & pelvis 
(abscess) 
15 745 
Lung 3D 14 550  
Chest  
(lung cancer) 
12 610 
Lung 4D 63 1750  - - - 
Prostate 16 570  
Abdomen & pelvis 
(abscess) 
15 745 
Brain  50 1500  
Head 
(acute stroke) 
60 970 
Head and Neck  49 2150  
Head 
(acute stroke) 
60 970 
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With regards to scans of the head, the current UK national diagnostic reference level for brain imaging is 60 mGy 
for CTDIvol (16 cm phantom). Allowing for the fact that the radiotherapy CT head scans in this audit are not for disease 
diagnosis, the proposed CTDIvol reference levels of 50 mGy for a radiotherapy CT brain scan and 49 mGy for head 
and neck scans would appear to be appropriate. The DLP reference levels for radiotherapy head scans are notably 
higher than the diagnostic NDRL of 970 mGy.cm, but this is to be expected due to the longer CT scan length 
required for the treatment planning process. For 3D lung, the proposed reference level of CTDIvol of 14 mGy is 
slightly higher than the NDRL of 12 mGy for diagnostic CT scans. In this case, there may be scope for extensive 
optimisation of practice to reduce doses in radiotherapy, but this must not be at the expense of appropriate image 
quality for treatment planning. 
Some technical challenges related to the CT scanners were identified during this audit. Firstly, older Toshiba 
scanners which, when AEC is in use, indicate maximum CTDIvol values, as opposed to the more typical mean 
CTDIvol from a patient scan. These systems had to be identified and removed from the CTDIvol data when 
determining reference values. These scanners can indicate considerably higher CTDIvol values than other scanners 
when scanning body regions where there is high variation in tissue density or thickness. This is also an important 
consideration when comparing scanner performance against the reference values proposed in this study; if a centre 
has an older generation Toshiba CT scanner, it may not be appropriate to compare median CTDIvol from local 
audits with the proposed national reference values. However, a comparison with the DLP and scan length reference 
values would be appropriate and allow optimisation of scan protocols, where necessary. Secondly, the lack of 
standardisation for phantom size used when displaying CTDIvol and DLP for scans of the head region is unhelpful 
and is a potential source of confusion. This was evidenced by one of the submitted sets of data where a correction 
had been incorrectly applied. Whilst the 32 cm phantom data collected during this audit has been converted to data 
for a 16 cm phantom by multiplying by a standardised figure of 2.06, the true correction factor used should be 
measured on each scanner since the conversion factor depends on scanner design. Published data (AAPM 2011) 
shows that this value can vary from 1.9 to 2.4 for different scanner types. The use of 32 cm phantom size on some 
scanners will primarily relate to the use of the large scan field of view as part of the treatment planning process. It 
is recommended, though, that scanners be set for head and neck and brain imaging, to show CTDIvol for a 16 cm 
phantom, or at the very least ensure appropriate conversions are performed before comparing with reference values. 
Both these points highlight the clear need for local operators to very clearly understand the technical features of 
their scanner. 
The information provided by centres on aspects related to imaging practice rather than scan protocol settings 
provided some interesting information and suggests that there is scope for sharing of good practice. Examples 
include one centre which is using a ‘no dose’ ultrasound option to review bladder filling, and 30% of other centres 
which undertake a low dose CT check scan instead prior to performing a prostate CT scan (which may reduce the 
number of repeat planning scans performed due to incorrect patient preparation). Some centres appear to be 
reducing the high dose delivered during 4D-lung scans by minimising scan length where supplementary data exists 
from 3D scanning of the extended anatomy.  
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With regards to the potential limitations of this study, variation in the source of the scan length information is a 
possible source of error in the results as the method for acquiring this information was not prescribed. The 
information available is dependent on the manufacturer and model, and the amount of over-scan along the patient 
axis (required for interpolation in helical scans) can vary between scanners; this may or may not have been 
included in the quoted scan length submitted to this audit. It is believed that many centres used the coordinates of 
the first and last images to infer the imaged scan length. There was also no correction applied to any of the datasets 
for displayed CTDIvol accuracy as this information was only provided for 50% of scanners. However, the mean 
reported discrepancy was low (7%), and the maximum (19%) was within normal manufacturer tolerances for this 
metric, and so there were no significant concerns about the quality of data submitted. Finally, no image quality data 
was collected from scanners contributing to this audit. In the pre-audit questionnaire a high proportion of centres 
expressed interest in participating in a follow-up study, specifically involving image quality assessment; it is 
therefore hoped that reference image quality metrics may be developed in the future to use alongside these dose 
index and scan length reference levels for the purposes of optimisation. 
Conclusions 
The first UK wide audit of dose indices for adult patients undergoing CT scans for radiotherapy planning has been 
completed. Reference values and achievable levels for CTDIvol, DLP and scan length have been proposed for seven 
common types of CT scan. Doses delivered by different scanners varied by a factor of up to 18 times for some scan 
types, indicating the need for reference dose index values and the possible need for scan protocol optimisation in 
some UK radiotherapy centres.  Scan protocol adjustments to change dose indices should always be accompanied 
by a rigorous quality assessment to ensure that the images remain suitable for radiotherapy planning. 
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